Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome-Reference-Cited by-同舟云学术

Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome

Published:2020-11 Issue:4 Volume: Page:841-847
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

File Danielle M.¹,Morgan Katherine P.²,Khagi Simon¹³

Affiliation:

1. Division of Hematology/Oncology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC

2. University of North Carolina Medical Center and University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC

3. Lineberger Comprehensive Cancer Center and Department of Neurosurgery, University of North Carolina School of Medicine, Chapel Hill, NC

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.20.00112

Reference66 articles.

1. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2. Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy

3. MGMTGene Silencing and Benefit from Temozolomide in Glioblastoma

4. IDH1andIDH2Mutations in Gliomas

5. PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test;The Journal of Molecular Diagnostics;2021-11

2. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples;JCO Precision Oncology;2021-08

3. Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers;Clinical Cancer Research;2021-02-05

4. Comprehensive genomic profiling of 30,000 consecutive solid tumors;2020-11-22